Keywords: laxoSmithKline, Avandia, EMEA, FDA, Europe, USA, Drug suspended

Double whammy for GlaxoSmithKline, as European regulator suspends Avandia and US FDA further restricts use of the diabetes drug

Article | 24 September 2010

Print This

GlaxoSmithKline (LSE: GSK) suffered a double dose of bad news yesterday, when the European Medicines Agency (EMEA) decided to withdraw ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in